Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eliot Hoffman

Cardiovascular Disease Fort Myers, FL Medical Doctor

NPI 1417952300 CMS profile 245464

13411 Parker Commons Blvd, Suite 101, Fort Myers, FL 33912

Open in the dashboard

General payments

$18,973

781 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eliot Hoffman of Fort Myers, FL is reported in the CMS Open Payments database as having received $18,973 across 781 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,648 52
2024 General $2,673 90
2023 General $3,480 136
2022 General $3,360 161
2021 General $3,915 171
2020 General $2,432 91
2019 General $1,466 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eliot Hoffman
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Eliot Hoffman were reported at $1,648. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Eliot Hoffman Cardiovascular Disease median Middle half National median
2019 $1,466 $450 $127–$1,392 $163
2020 $2,432 $242 $77–$751 $114
2021 $3,915 $335 $101–$1,037 $132
2022 $3,360 $395 $121–$1,211 $149
2023 $3,480 $443 $136–$1,283 $160
2024 $2,673 $450 $136–$1,323 $164
2025 $1,648 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CVRx, Inc. $4,270 76 payments
  2. Abbott Laboratories $3,127 58 payments
  3. Janssen Pharmaceuticals, Inc $1,391 120 payments
  4. Novartis Pharmaceuticals Corporation $1,336 73 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,169 52 payments
  6. Amgen Inc. $1,050 68 payments
  7. AstraZeneca Pharmaceuticals LP $771 47 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $710 32 payments
  9. Merck Sharp & Dohme Corporation $691 34 payments
  10. Pfizer Inc. $678 50 payments
  11. Other $3,780 171 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,790 769 payments
  2. Education $183 12 payments
Products named General payments · program years 2019–2025
  1. Barostim Neo System $4,270 76 payments
  2. XARELTO $1,386 119 payments
  3. Repatha $989 65 payments
  4. JARDIANCE $819 37 payments
  5. ENTRESTO $803 46 payments
  6. VERQUVO $782 38 payments
  7. Kerendia $710 32 payments
  8. LEQVIO $491 24 payments
  9. ELIQUIS $470 35 payments
  10. Confirm Rx $470 15 payments
  11. Other $9,511 411 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

7,342

Median for Cardiology: 2,533

Drug cost

$2,400,637

Median for Cardiology: $485,213

Branded share of claims

29.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 710 $967,294
Entresto Sacubitril/Valsartan Brand 250 $374,452
Vyndamax Tafamidis Brand 12 $287,430
Xarelto Rivaroxaban Brand 182 $260,514
Repatha Sureclick Evolocumab Brand 127 $142,090
Jardiance Empagliflozin Brand 82 $104,849
Farxiga Dapagliflozin Propanediol Brand 53 $58,412
Multaq Dronedarone Hcl Brand 14 $31,883
Verquvo Vericiguat Brand 23 $26,374
Wegovy Semaglutide Brand 12 $15,930

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$285,224

Of which drugs: $1,999

Medicare patients

1,087

Average age 79

Services billed

3,941

451 women, 636 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 56%
Atrial fibrillation 43%
Diabetes 35%
Chronic kidney disease 32%
Heart failure 24%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 56 224 $1,986

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$195 82 —
Arcalyst
$160 — —
Kerendia
$157 — —
LEQVIO
$120 — —
Repatha
$118 127 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

781 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record